David H. Collier
M.D.
Professor of Medicine

Medical School:  Washington University School of Medicine, St. Louis, Missouri

Postgraduate training:

When arrived at UCD: 1983

Past and current professional positions:

Awards and Honors received:

Excellence in Teaching Award for year 1998, Medical Student Council, University of Colorado Denver

6^th Annual Faculty Outstanding Clinician Award of the Year 2000 by the Denver Health and Hospital Medical Staff

Consumers' Research Council of America Guide to America's Top Physicians, 2003-2007

5280 Denver Mile-High Magazine-Top Doctor in Rheumatology as voted by physicians in Denver metropolitan area 2005-2006

Arthritis Foundation, Rocky Mountain Chapter Evening of the Stars Physician of the Year Award, 2005

Description in a couple of paragraphs about research interests and/or clinical trial interests:

My main interest is in clinical trials regarding Systemic Sclerosis and Raynaud’s Phenomenon. I am interested in the natural history and effect of therapeutic interventions in Systemic Sclerosis and Raynaud’s Phenomenon. Over the last 12 years I have been involved in looking at D-Penicillamine, Ketotifen, Relaxin, and Cyclophosphamide in Systemic Sclerosis. I have also studied Iloprost and an a-2-adrenoceptor inhibitor, OPC-28326 in Raynaud’s Phenomenon.

My second interest is in patients with concomitant Hepatitis C infection and an autoimmune disease, such as Rheumatoid Arthritis. We are interested in seeing what effect disease modifying agents used to treat rheumatoid arthritis have on hepatitis C in these patients. Similarly, we are interested in what effect treatments, such as a-interferon and Ribaviron, have on patients with rheumatoid arthritis.

I am a founding member of the Scleroderma Clinical Trials Consortium

Representative publications:

1.         Enzenauer RJ, Collier DH, Lopez LR.  Anticardiolipin antibodies in scleroderma.  Journal of Clinical Rheumatology 12:324-326, 2006

2.         Khanna D, Furst DE,  Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FW, Moreland L, Silver R, Steen VD,          Weisman M, Mayes MD , Collier D, Medsger TA, Seibold JA.  Responsiveness of the SF-36 and health assessment questionnaire disability index (HAQ-           DI) in systemic sclerosis clinical trial.  J Rheumatol 32:832-40,2005.

3.         Gibney EM, Parikh CR, Hani A, Fischer MJ, Collier D, Weisman AC.  Kidney transplantation in systemic sclerosis improves survival and may mmodulate   disease activity.   American J Transplant  4:2027-2031, 2004

4.         Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White B, Weisman M, Barr W, Moreland L, Martin R, Medsger TA, Steen V, Collier D,        Weinstein A, Lally E, Varga J, Weiner SR, Andres B, Abeles M, Peter JB, Seibold JR: Effects of the American College of Rheumatology systemic sclerosis             trial-guidelines on the nature of systemic sclerosis patients entering a clinical trial. Rheumatology 40:615-622, 2001.

5.         Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen V, Martin RW,      Collier D, Weinstein A, Lally E, Barga J, Weinser SR, Andrews B, Abeles M, Seibold JR: The disability index of the health assessment questionnaire is a         predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 44(3): 653-661, 2001.

6.         Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martain      RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andres B, Abeles M, Furst DE: Skin thickness score as a predictor and correlate of outcome             in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43:2445-2454, 2000.

7.         Pacheco TR, Weston WL, Giclas PC, Collier DH, Lee LA: Three generations of patients with lupus erythematosus and hereditary angioedema. Am J Med             109:256-257, 2000.

8.         Seibold JR, Korn JH Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier DH, Wigley FM, Merkel             PA, Csuka ME, Hsu U, Rocco S, Erikson M, Hannigan J, Harkonene WS, Sanders ME: Recombinant human relaxin in the treatment of scleroderma. A    randomized, double-blind, placebo-controlled trial. Ann Intern Med 132:871-879, 2000.